A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park J.-W. | - |
dc.contributor.author | Ji H.K. | - |
dc.contributor.author | Seok K.K. | - |
dc.contributor.author | Keon W.K. | - |
dc.contributor.author | Kyung W.P. | - |
dc.contributor.author | Choi J.-I. | - |
dc.contributor.author | Woo J.L. | - |
dc.contributor.author | Kim C.-M. | - |
dc.contributor.author | Byung H.N. | - |
dc.date.available | 2020-11-03T11:44:11Z | - |
dc.date.issued | 2008-12-01 | - |
dc.identifier.issn | 0161-5505 | - |
dc.identifier.issn | 1535-5667 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/17439 | - |
dc.description.abstract | Because 18F-FDG PET has insufficient sensitivity for the detection of hepatocellular carcinoma (HCC), 11C-acetate PET has been proposed as another technique for this use. We prospectively evaluated the value of PET/CT using these 2 tracers for the detection of primary and metastatic HCC. Methods: One hundred twelve patients (99 with HCC, 13 with cholangiocellular carcinoma) underwent biopsy and 18F-FDG and 11C-acetate PET/CT. Results: The overall sensitivities of 18F-FDG, 11C-acetate, and dual-tracer PET/CT in the detection of 110 lesions in 90 patients with primary HCC were 60.9%, 75.4%, and 82.7%, respectively. Elevated serum α-fetoprotein levels, an advanced tumor stage, portal vein tumor thrombosis, large tumors, and multiple tumors were significantly associated with positive 18F-FDG PET/CT results. Uptake of 11C-acetate was associated with large and multiple tumors. For 18F-FDG, the sensitivities according to tumor size (1-2, 2-5, and ≥5 cm) were 27.2%, 47.8%, and 92.8%, respectively; for 11C- acetate, these respective values were 31.8%, 78.2%, and 95.2%. 18F-FDG was more sensitive in the detection of poorly differentiated HCC. Overall survival was lower in patients with 18F-FDG PET/CT positive for all indexed lesions than in those with FDG negative or partially positive through the entire follow-up period. In analysis based on biopsied lesions, the sensitivity of 18F-FDG PET/CT was 64.4% for primary HCC and 84.4% for 11C-acetate PET/CT. The overall sensitivities of 18F-FDG, 11C-acetate, and dual-tracer PET/CT for 35 metastatic HCCs were 85.7%, 77.0%, and 85.7%, respectively. There was no significant difference in the sensitivity of tracers according to metastatic tumor size, location, or differentiation. Conclusion: The addition of 11C-acetate to 18F-FDG PET/CT increases the overall sensitivity for the detection of primary HCC but not for the detection of extrahepatic metastases. 18F-FDG, 11C-acetate, and dual-tracer PET/CT have a low sensitivity for the detection of small primary HCC, but 18F-FDG PET/CT has a relatively high sensitivity for the detection of extrahepatic metastases of HCC. Copyright © 2008 by the Society of Nuclear Medicine, Inc. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.2967/jnumed.108.055087 | - |
dc.identifier.scopusid | 2-s2.0-57149101558 | - |
dc.identifier.bibliographicCitation | Journal of Nuclear Medicine, v.49, no.12, pp 1912 - 1921 | - |
dc.citation.title | Journal of Nuclear Medicine | - |
dc.citation.volume | 49 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1912 | - |
dc.citation.endPage | 1921 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | acetic acid c 11 | - |
dc.subject.keywordPlus | alpha fetoprotein | - |
dc.subject.keywordPlus | fluorodeoxyglucose f 18 | - |
dc.subject.keywordPlus | gadolinium pentetate | - |
dc.subject.keywordPlus | gadolinium pentetate meglumine | - |
dc.subject.keywordPlus | hepatitis B surface antigen | - |
dc.subject.keywordPlus | superparamagnetic iron oxide | - |
dc.subject.keywordPlus | acetic acid derivative | - |
dc.subject.keywordPlus | carbon | - |
dc.subject.keywordPlus | carbon 11 acetate | - |
dc.subject.keywordPlus | carbon-11 acetate | - |
dc.subject.keywordPlus | diagnostic agent | - |
dc.subject.keywordPlus | fluorodeoxyglucose f 18 | - |
dc.subject.keywordPlus | radiopharmaceutical agent | - |
dc.subject.keywordPlus | unclassified drug | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | bile duct carcinoma | - |
dc.subject.keywordPlus | cancer diagnosis | - |
dc.subject.keywordPlus | cancer localization | - |
dc.subject.keywordPlus | cancer size | - |
dc.subject.keywordPlus | cancer staging | - |
dc.subject.keywordPlus | cell differentiation | - |
dc.subject.keywordPlus | computer assisted tomography | - |
dc.subject.keywordPlus | disease association | - |
dc.subject.keywordPlus | drug excretion | - |
dc.subject.keywordPlus | drug uptake | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | liver biopsy | - |
dc.subject.keywordPlus | liver cell carcinoma | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | metastasis | - |
dc.subject.keywordPlus | multiple cancer | - |
dc.subject.keywordPlus | overall survival | - |
dc.subject.keywordPlus | portal vein thrombosis | - |
dc.subject.keywordPlus | positron emission tomography | - |
dc.subject.keywordPlus | primary tumor | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | prognosis | - |
dc.subject.keywordPlus | prospective study | - |
dc.subject.keywordPlus | protein blood level | - |
dc.subject.keywordPlus | sensitivity analysis | - |
dc.subject.keywordPlus | spiral computer assisted tomography | - |
dc.subject.keywordPlus | tumor biopsy | - |
dc.subject.keywordPlus | tumor differentiation | - |
dc.subject.keywordPlus | computer assisted tomography | - |
dc.subject.keywordPlus | evaluation | - |
dc.subject.keywordPlus | image subtraction | - |
dc.subject.keywordPlus | incidence | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | liver cell carcinoma | - |
dc.subject.keywordPlus | liver tumor | - |
dc.subject.keywordPlus | metastasis | - |
dc.subject.keywordPlus | methodology | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | mortality | - |
dc.subject.keywordPlus | positron emission tomography | - |
dc.subject.keywordPlus | reproducibility | - |
dc.subject.keywordPlus | risk assessment | - |
dc.subject.keywordPlus | risk factor | - |
dc.subject.keywordPlus | sensitivity and specificity | - |
dc.subject.keywordPlus | statistics | - |
dc.subject.keywordPlus | survival | - |
dc.subject.keywordPlus | survival rate | - |
dc.subject.keywordPlus | Acetates | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Carbon | - |
dc.subject.keywordPlus | Carcinoma, Hepatocellular | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Fluorodeoxyglucose F18 | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Incidence | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | Liver Neoplasms | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Positron-Emission Tomography | - |
dc.subject.keywordPlus | Prognosis | - |
dc.subject.keywordPlus | Prospective Studies | - |
dc.subject.keywordPlus | Radiopharmaceuticals | - |
dc.subject.keywordPlus | Reproducibility of Results | - |
dc.subject.keywordPlus | Risk Assessment | - |
dc.subject.keywordPlus | Risk Factors | - |
dc.subject.keywordPlus | Sensitivity and Specificity | - |
dc.subject.keywordPlus | Subtraction Technique | - |
dc.subject.keywordPlus | Survival Analysis | - |
dc.subject.keywordPlus | Survival Rate | - |
dc.subject.keywordPlus | Tomography, X-Ray Computed | - |
dc.subject.keywordAuthor | Acetate | - |
dc.subject.keywordAuthor | FDG | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Hepatology | - |
dc.subject.keywordAuthor | Oncology | - |
dc.subject.keywordAuthor | PET/CT | - |
dc.subject.keywordAuthor | Sensitivity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.